CJC 1295: Growth Hormone Releasing Peptide
Purity: 98% (HPLC on request)
Molecular Formula: C165H269N47O46 Molecular Weight: 3647.15 CAS No.:863288-34-0

Description
CJC 1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC 1295 shown potential to increase growth hormone and IGF-I secretion and effects, but it has been able to do so in very large amounts. CJC 1295 Stimulates Growth Hormone Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis thereby promoting growth.

CJC 1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog.

One of the advantages of CJC 1295 over traditional GHRH or rHGH is its ability to bio conjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. Another benefit of CJC 1295 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. Clinical studies have shown that a once-daily administration of CJC 1295 normalizes the GHRH response and can induce significantly deeper sleep.

Dosing Protocol
Use 1 vial daily 5 days out of 7 mixed with saline.

Clinical Research
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC 1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, and Lawrence A. Frohman.
WinPharm Associates (S.L.T., A.N.), Alamo, California 94507; ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre´al, Que´be´c, Canada; and Section of Endocrinology, Department of Medicine, University of Illinois (L.A.F.), Chicago, Illinois 60612
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC 1295, a long-acting GHRH analog.
Design: The study design was two randomized, placebo-controlled, double blind, ascending dose trials with durations of 28 and 49 d.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy horses and was safe and relatively well tolerated. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutically agent.